INSERM INSTITUTE NATIONAL DE LA SANTE ET DE LA RECH MEDICALE has a total of 17 patent applications. It increased the IP activity by 100.0%. Its first patent ever was published in 2015. It filed its patents most often in United States. Its main competitors in its focus markets biotechnology, pharmaceuticals and measurement are OSTEONEUROGEN, GDANSKI UNIV MEDYCZNY and ZHU ZHENGLUN.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 17 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Measurement | |
#4 | Foods and drinks | |
#5 | Computer technology | |
#6 | Organic fine chemistry | |
#7 | Micro-structure and nano-technology |
# | Technology | |
---|---|---|
#1 | Analysing materials | |
#2 | Medical preparations | |
#3 | Microorganisms | |
#4 | Therapeutic chemical compounds | |
#5 | Peptides | |
#6 | Measuring microorganism processes | |
#7 | Enzymes | |
#8 | Nanostructure applications | |
#9 | Sugars | |
#10 | Healthcare informatics |
# | Name | Total Patents |
---|---|---|
#1 | Boulanger-Robert Chantal | 2 |
#2 | Rautou Pierre-Emmanuel | 2 |
#3 | Al-Daccak Reem | 1 |
#4 | Van Endert Peter | 1 |
#5 | Sormani Le Bourhis Laura | 1 |
#6 | Gissot Arnaud | 1 |
#7 | Rochotte Julia | 1 |
#8 | Culina Slobodan | 1 |
#9 | Gines Silvia | 1 |
#10 | Barthelemy Philippe | 1 |
Publication | Filing date | Title |
---|---|---|
US2021079100A1 | Methods and compositions for treating hyperpigmentation disorders | |
US2020181607A1 | Tetramolecular parallel g-quadruplex-forming hydrophobically modified oligonucleotides | |
US2020316102A1 | Methods and pharmaceutical composition for the treatment of neurodegenerative disease | |
US2020225247A1 | Methods and kits for predicting the transplantation-free survival time of patients suffering from cirrhosis | |
US2020009224A1 | Methods of boosting thymic regeneration in patients suffering from a thymic injury by using rankl | |
US2018251731A1 | Subpopulation of cd8+cd45rclow tregs and uses thereof | |
US2017016074A1 | Methods and kits for classifying diffuse large B-cell lymphomas (DLBCLs) into GCB-DLBCLs or into ABC-DLBCLs |